کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10833078 | 1065784 | 2014 | 8 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Sapropterin dihydrochloride use in pregnant women with phenylketonuria: An interim report of the PKU MOMS sub-registry
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
PKUMedDRAtetrahydrobiopterinBH4OFCLMPPHESAECDCAPGAROccipitofrontal circumferencePAHSapropterinphenylketonuria - فنیل کتونوریlast menstrual period - آخرین دوره قاعدگیMedical Dictionary for Regulatory Activities - دیکشنری پزشکی برای فعالیت های نظارتیWorld Health Organization - سازمان بهداشت جهانیbody mass index - شاخص توده بدنBMI - شاخص توده بدنیIdentification - شناساییadverse event - عارضه جانبی یا عوارض جانبیSerious adverse event - عوارض جانبی جدیPhenylalanine hydroxylase - فنیلالانین هیدروکسیلازPhenylalanine - فنیلآلانینCenters for Disease Control and Prevention - مراکز کنترل و پیشگیری از بیماریHyperphenylalaninemia - هیپرفنیلالانینمیWHO - که
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
زیست شیمی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
For pregnant women with phenylketonuria (PKU), maintaining blood phenylalanine (Phe) < 360 μmol/L is critical due to the toxicity of elevated Phe to the fetus. Sapropterin dihydrochloride (sapropterin) lowers blood Phe in tetrahydrobiopterin (BH4) responsive patients with PKU, in conjunction with a Phe-restricted diet, but clinical evidence supporting its use during pregnancy is limited. As of June 3, 2013, the Maternal Phenylketonuria Observational Program (PKU MOMS) sub-registry contained data from 21 pregnancies - in women with PKU who were treated with sapropterin either before (N = 5) or during (N = 16) pregnancy. Excluding data for spontaneous abortions (N = 4), the data show that the mean of median blood Phe [204.7 ± 126.6 μmol/L (n = 14)] for women exposed to sapropterin during pregnancy was 23% lower, and had a 58% smaller standard deviation, compared to blood Phe [267.4 ± 300.7 μmol/L (n = 3)] for women exposed to sapropterin prior to pregnancy. Women on sapropterin during pregnancy experienced fewer blood Phe values above the recommended 360 μmol/L threshold. When median blood Phe concentration was < 360 μmol/L throughout pregnancy, 75% (12/16) of pregnancy outcomes were normal compared to 40% (2/5) when median blood Phe was > 360 μmol/L. Severe adverse events identified by the investigators as possibly related to sapropterin use were premature labor (N = 1) and spontaneous abortion (N = 1) for the women and hypophagia for the offspring [premature birth (35w4d), N = 1]. One congenital malformation (cleft palate) of unknown etiology was reported as unrelated to sapropterin. Although there is limited information regarding the use of sapropterin during pregnancy, these sub-registry data show that sapropterin was generally well-tolerated and its use during pregnancy was associated with lower mean blood Phe. Because the teratogenicity of elevated maternal blood Phe is without question, sapropterin should be considered as a treatment option in pregnant women with PKU who cannot achieve recommended ranges of blood Phe with dietary therapy alone.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Molecular Genetics and Metabolism - Volume 112, Issue 1, May 2014, Pages 9-16
Journal: Molecular Genetics and Metabolism - Volume 112, Issue 1, May 2014, Pages 9-16
نویسندگان
Dorothy K. Grange, Richard E. Hillman, Barbara K. Burton, Shoji Yano, Jerry Vockley, Chin-To Fong, JoEllen Hunt, John J. Mahoney, Jessica L. Cohen-Pfeffer,